Gene · 100862689
ERVK-3: endogenous retrovirus group K member 3
12 sourcesgene-search-2026-11-11-0.2.0
Download JSON
Cite this record
ConductScience Library. ERVK-3: endogenous retrovirus group K member 3. Genes, record 100862689. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/100862689
On this page
Gene
Proteins0
Reviewed human proteins whose Swiss-Prot entry states the gene.
None in this release.
Patents0
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
None in this release.
Drugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants861
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ERVK-3 papers | Newest fiscal year |
|---|---|---|---|
| P30CA046934 | University of Colorado Cancer Center Support Grant | 3 | 2025 |
| T32AR007279 | Immunobiology of the Rheumatic Diseases | 3 | 2025 |
| U24AG021886 | National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) | 3 | 2025 |
| ZIAHL006223 | The role of the intracellular complement system - the complosome - in Th1 biology | 3 | 2025 |
| P30AG062715 | Wisconsin Alzheimer's Disease Research Center | 2 | 2025 |
| P30AG066509 | University of Washington Alzheimer's Disease Research Center | 2 | 2025 |
| P30AG072972 | UC Davis Alzheimer's Disease Research Center | 2 | 2025 |
| P30CA016520 | Abramson Cancer Center Support Grant | 2 | 2025 |
| P30ES005605 | Environmental Health Sciences Research Center | 2 | 2025 |
| P30EY016665 | Core Grant for Vision Research | 2 | 2025 |
1 to 10 of 861Source NIH's project files
See all 861 nih grantsPapers2,087
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cold agglutinin disease: pathophysiology, diagnosis, and the evolving therapeutic landscape. | Blood Res | 2026 | 42696222 | PubTator, text mining | PubMed |
| Clinical improvement of acquired partial lipodystrophy in an adolescent with C3 glomerulopathy treated with pegcetacoplan. | Pediatr Nephrol | 2026 | 42690456 | PubTator, text mining | PubMed |
| Complement-Targeted Therapies in Glioblastoma: A Systematic Review. | Biomedicines | 2026 | 42652085 | PubTator, text mining | PubMed |
| The endurance effort on a mechanical treadmill does not activate the complement system among trained young women. | PLoS One | 2026 | 42461968 | PubTator, text mining | PubMed |
| Malondialdehyde epitopes exposed on dying cells are potent modulators of complement activity and efferocytosis. | J Lipid Res | 2026 | 42425490 | PubTator, text mining | PubMed |
| HSV-2 gC2 mRNA immunization in mice protects by producing antibodies that bind immune evasion epitopes. | PLoS Pathog | 2026 | 42348550 | PubTator, text mining | PubMed |
| Activation of the Complement System: Morphological Differences in the Surface of PIBCA Nanoparticles Coated with Polysaccharides. | ACS Nanosci Au | 2026 | 42327943 | PubTator, text mining | PubMed |
| Correction: Sez6L2 inhibits complement by facilitating factor I cleavage of C3b and accelerating the decay of C3 convertases. | Front Immunol | 2026 | 42253996 | PubTator, text mining | PubMed |
| The Therapeutic Potential of Complement Inhibitors in Xenoreactive Human Complement-Dependent Cytotoxicity in Vitro. | Xenotransplantation | 2026 | 42227943 | PubTator, text mining | PubMed |
| Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN: Phase 3 VALIANT Subgroup Analysis. | Clin J Am Soc Nephrol | 2026 | 42133432 | PubTator, text mining | PubMed |
1 to 10 of 2,087
See all 2,087 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/100862689
GET https://conductscience.org/api/genes/v1/100862689/grants?page=2